




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|--|
| (51) International Patent Classification ⁶ : C07D 333/38, A61K 31/38 | A1 | (11) International Publication Number: WO 98/25919 (43) International Publication Date: 18 June 1998 (18.06.98) |
| (21) International Application Number: PCT/JP97/04527 (22) International Filing Date: 10 December 1997 (10.12.97) (30) Priority Data: 8/333495 13 December 1996 (13.12.96) JP 9/254001 19 September 1997 (19.09.97) JP (71) Applicant (for all designated States except US): SHIONOGI & CO., LTD. [JP/JP]; 1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): HONMA, Tsunetoshi [JP/JP]; 117-42, Aoyamada, Ikoma-shi, Nara 630-02 (JP). HIRAMATSU, Yoshiharu [JP/JP]; 1-4-13, Mizuhai, Higashiosaka-shi, Osaka 578 (JP). ARIMURA, Akinori [JP/JP]; 1-7-32-304, Minamisumiyoshi, Sumiyoshi-ku, Osaka-shi, Osaka 558 (JP). (74) Agent: YAMAUCHI, Hideaki; 1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP). | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: BENZOTHIOPHENECARBOXAMIDE DERIVATIVES AND PGD ₂ ANTAGONISTS COMPRISING THEM (57) Abstract <p>A compound, a pharmaceutically acceptable salt thereof, or a hydrate thereof having PGD₂-antagonistic activities, inhibitory activities against infiltration of eosinophils, and being useful as a drug for treating diseases, such as systemic mastocytosis and disorder of systemic mast cell activation, as well as tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion injury, inflammation and atopic dermatitis, which is shown by formula (I), is provided.</p> <div style="text-align: right;">  </div> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

DESCRIPTION

BENZOTHIOPHENECARBOXAMIDE DERIVATIVES AND PGD₂
ANTAGONISTS COMPRISING THEM

FIELD OF THE INVENTION

The present invention relates to benzothiophenecarboxamide derivatives, the intermediates therefor, pharmaceutical compositions comprising them, PGD₂ (prostaglandin D₂) antagonists comprising them, and drugs for treating nasal blockage comprising them.

BACKGROUND OF THE INVENTION

Some of bicyclic amide derivatives analogues to the compounds of the present invention have been described that they are useful as thromboxane A₂ (TXA₂) antagonists (Japanese Patent Publication (Kokoku) No. 53295/1991). However, in the Japanese Patent Publication (Kokoku) No. 53295/1991, it has only been described that the compounds are useful as TXA₂ antagonists, but there is no suggestion of the usefulness thereof as PGD₂ antagonists as found in the present invention. On the other hand, in Japanese Patent Publication (Kokoku) No.79060/1993, Japanese Patent Publication (Kokoku) No.23170/1994 and Chem. Pharm. Bull. Vol.37, No.6 1524-1533 (1989), it has been described bicyclic amide derivatives, which are intermediates for bicyclic sulfonamide derivatives. However, the compounds disclosed therein are different from those of the present invention in the species of substituents at the amide portion. And some of the compounds analogues to the

compounds of the present invention has been described that they are useful as PGD₂ antagonists in WO 97/00853. However, there is no suggestion that the compounds disclosed in WO 97/00853 possess an inhibitory activity against infiltration of eosinophils.

TXA₂ has been known to have various activities such as platelet aggregation, thrombogenesis, etc. The TXA₂ antagonists have therefore been considered to be useful as anti-thrombotic agents as well as drugs in the treatment of myocardial infarction or asthma.

On the other hand, the PGD₂ antagonists of the present invention are useful in the improvement of conditions due to excessive production of PGD₂, particularly as drugs for treating diseases in which mast cell dysfunction is involved, for example, systemic mastocytosis and disorder of systemic mast cell activation as well as for tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion injury, inflammation, and atopic dermatitis.


PGD₂ is a major prostanoid that is produced in and released from mast cells in which it is produced through PGG₂ and PGH₂ from arachidonic acid by the action of cyclooxygenase activated by immunological or unimmunological stimulation. PGD₂ has various potent physiological and pathological activities. For example, PGD₂ can cause strong tracheal contraction to lead to bronchial asthma, and in a systemic allergic state, it dilates the peripheral vessels to cause an anaphylactic shock. Especially, much attention has been paid to the theory that PGD₂ is one of the causal substances responsible to the onset of nasal blockage in the allergic rhinitis. Therefore, it has been proposed to develop an

inhibitor against the biosynthesis of PGD_2 or an antagonist of PGD_2 receptor as a drug for the reduction of nasal blockage. However, the inhibitor of PGD_2 biosynthesis possibly much affects the synthesis of prostaglandins in other parts of organisms, and therefore, it is desirable to develop an antagonist (blocker) specific to the PGD_2 receptor.

DISCLOSURE OF THE INVENTION

The present inventors have studied intensively to develop PGD_2 receptor antagonists (blockers) specific to the PGD_2 receptor, and found that a series of compounds of the formula (I) below, pharmaceutically acceptable salts thereof, or hydrates thereof possess a potent activity as PGD_2 receptor antagonists and a inhibitory activity against infiltration of eosionophils, and are useful as drugs for treating nasal blockage. The compounds of the present invention having PGD_2 antagonist activity are different from the known TXA_2 antagonists in the active site and mechanism, application, and character.


Accordingly, the present invention provides a compound of the formula (I):




wherein



represents




R represents hydrogen, alkyl, alkoxy, halogen, hydroxy, acyloxy or optionally substituted arylsulfonyloxy, X represents hydrogen or alkyl, and the double bond on the α -chain has E configuration or Z configuration, provided that the compound of the formula:




wherein R^{1a} represents hydrogen, alkyl or alkoxy, X is as defined above, and the double bond on the α -chain has E configuration or Z configuration is excluded, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

In the present specification, in the formula (I), the linkage represented by the group:



wherein X is as defined above;

is referred to as α -chain, the linkage represented by the group:



wherein R is as defined above;

is referred to as ω -chain.


The double bond on the α -chain has E configuration or Z configuration.

BRIEF DESCRIPTION OF DRAWING


Figure 1 shows the activity of the compound (IA-a-5) against infiltration of eosinophils in the nasal cavity induced by an antigen. In the figure, the white column indicates a group to which saline was inhaled instead of ovalbumin; the black column indicates a group to which an antigen was inhaled to induce an inflammatory reaction but not administered the compound (IA-a-5); and the gray columns indicate groups to which an antigen was inhaled to induce an inflammatory reaction and administered the compound (IA-a-5). The asterisk ** indicate significantly different from vehicle at $p < 0.01$.

BEST MODE FOR CARRYING OUT THE INVENTION

More specifically, the compounds (I) can be exemplified by a compound of the formula (IA):




wherein R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration, provided that the compound of the formula:



wherein R^{1a} represents hydrogen, alkyl or alkoxy, X is as defined above, and the double bond on the α -chain has E configuration or Z configuration is excluded, a pharmaceutically acceptable salt thereof, or a hydrate thereof.


Similarly, the compounds (I) can also be exemplified by the compound of

the formula (IB):



wherein R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

More specifically, the compounds of the formula (IA) can be exemplified by:




wherein R¹ represents halogen, hydroxy, acyloxy or optionally substituted arylsulfonyloxy, R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration.

Preferred examples of the compounds include those of the formula (IA-

a), (IA-b), (IA-c), (IA-d) and (IA-b'). Particularly, preferred examples of the compounds include those of the formula (IA-a).

Similarly, the compounds of the formula (IB) can be exemplified by:



wherein R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration.

Preferred examples of the compounds include those of the formula (IB-a') and (IB-b').

Another examples of the compounds include those wherein the double bond on the α -chain has E configuration of the formula (I), (IA), (IB), (IA-a), (IA-b), (IA-c), (IA-d), (IA-b'), (IB-a') and (IB-b').


Similarly, examples of the compounds include those wherein the double bond on the α -chain has Z configuration of the formula (I), (IA), (IB), (IA-a), (IA-b), (IA-c), (IA-d), (IA-b'), (IB-a') and (IB-b').

Similarly, examples of the compounds include those wherein R is bromo,

fluoro, hydroxy, acetoxy, or phenylsulfonyl, and X is hydrogen of the formula (I), (IA), (IB), (IA-a), (IA-b), (IA-c), (IA-d), (IA-b'), (IB-a') and (IB-b').


Similarly, examples of the compounds include those wherein R is hydrogen, methyl or methoxy, and X is hydrogen of the formula (I), (IA), (IB), (IA-b), (IA-c), (IA-d), (IA-b'), (IB-a') and (IB-b').

As for examples of the intermediates include compounds of the formula (V):




wherein the Y ring and R are as defined above.

Another examples of the intermediates include compounds of the formula (VI):



wherein the Y ring and R are as defined above.


Another examples of the intermediates include compounds of the formula (IIIa):




wherein R² represents acyloxy or optionally substituted arylsulfonyloxy, and R³ represents hydroxy or halogen.

Preferred examples of the compounds include those of the formula

(IIIb):



wherein R² and R³ are as defined above, or the formula (IIIc):



wherein R² and R³ are as defined above.

Particularly, preferred examples of the compounds include those wherein R³ is hydroxy, or R² is phenylsulfonyloxy or acetyloxy of the formula (IIIa), (IIIb) and (IIIc).

Another embodiment of the present invention is a pharmaceutical composition comprising the compound of the formula (I) or a PGD₂ antagonist comprising them. Particularly, the compounds of the formula (I) are useful as drugs for treating nasal blockage. PGD₂ antagonists in the present invention inhibit infiltration of inflammatory cells. The term "inflammatory cells" means all of lymphocytes, eosionophils, neutrophils, and macrophages, and particularly, eosionophils.

The compounds (I) in the present invention show PGD₂-antagonistic activities through the binding to PGD₂ receptor, so they are useful as drugs for treating diseases in which mast cell dysfunction due to excessive production of PGD₂ is involved. For example, the compounds (I) are useful as drugs for treating diseases, such as systemic mastocytosis and disorder of systemic mast cell activation as well as for tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion injury, inflammation and

atopic dermatitis. Moreover, the compounds (I) of the present invention possess an activity inhibiting infiltration of inflammatory cells. The compounds (I) are especially useful as drugs for treating nasal blockage.

The terms used throughout the present specification are as defined below.

The term "halogen" means fluoro, chloro, bromo and iodo.

The term "acyl" in the "acyloxy" means C₁-C₉ acyl derived from aliphatic carboxylic acid, for example, formyl, acetyl, propionyl, butyryl, valeryl, and the like. The term "acyloxy" means acyloxy derived from the above-mentioned acyl, for example, acetoxo, propionyloxy, butyryloxy, valeryloxy, and the like.

The term "aryl" means C₆ - C₁₄ monocyclic or condensed ring, for example, phenyl, naphthyl (e.g., 1-naphthyl, 2-naphthyl), anthryl (e.g., 1-anthryl, 2-anthryl, 9-anthryl), and the like. The substituents on the aryl include alkyl, alkoxy, halogen, hydroxy, and the like.

The term "alkyl" means C₁ - C₆ straight or branched chain alkyl, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, neopentyl, t-pentyl, hexyl, and the like.

The term "alkoxy" means C₁ - C₆ alkoxy, for examples, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, and the like.

Examples of salts of the compounds (I) include those formed with an alkali metal (e.g., lithium, sodium or potassium), an alkali earth metal (e.g., calcium), an organic base (e.g., tromethamine, trimethylamine, triethylamine, 2-


aminobutane, t-butylamine, diisopropylethylamine, n-butylmethylamine, cyclohexylamine, dicyclohexylamine, N-isopropylcyclohexylamine, furfurylamine, benzylamine, methylbenzylamine, dibenzylamine, N,N-dimethylbenzylamine, 2-chlorobenzylamine, 4-methoxybenzylamine, 1-naphthalenemethylamine, diphenylbenzylamine, triphenylamine, 1-naphthylamine, 1-aminoanthracene, 2-aminoanthracene, dehydroabiethylamine, N-methylmorpholine or pyridine), an amino acid (e.g., lysine, or arginine), and the like.

Examples of hydrates of the compounds represented by the formula (I) may be coordinated with the compound (I) at the optional proportion.

The compounds represented by the formula (I) represent the optional steric configuration, the double bond on the α -chain has E configuration or Z configuration, the bond binding to the bicyclic ring represents R configuration or S configuration, and include the all isomers (diastereomers, epimers, enantiomers, and the like), racemates and mixtures thereof.

General processes for the preparation of the compounds in the present invention can be illustrated as follows. In the case of the compounds having substituents which interfere the reaction, such substituents may preliminarily be protected with protecting groups, and they may be removed in the suitable step.

Process 1




wherein the Y ring, X and R are as defined above, and the double bond on the α -chain has E configuration or Z configuration.

The compounds of the formula (I) as shown in the above process 1 can be prepared by reacting a carboxylic acid of the formula (III) or their reactive derivatives with an amino compounds of the formula (II).

In this process, the starting compounds (II) wherein



is




are described in the Japanese Patent Publication (Kokoku) No. 23170/1994.

The compounds (II) wherein



is



are described in the Japanese Patent Publication (Kokai) Nos. 49/1986 and 180862/1990.

The carboxylic acid of the formula (III) includes 4-bromobenzo[b]thiophene-3-carboxylic acid, 5-bromobenzo[b]thiophene-3-carboxylic acid, 6-bromobenzo[b]thiophene-3-carboxylic acid, 7-bromobenzo[b]thiophene-3-carboxylic acid, 5-fluorobenzo[b]thiophene-3-carboxylic acid, 6-fluorobenzo[b]thiophene-3-carboxylic acid, 4-hydroxybenzo[b]thiophene-3-carboxylic acid, 5-hydroxybenzo[b]thiophene-3-carboxylic acid, 6-hydroxybenzo[b]thiophene-3-carboxylic acid, 7-hydroxybenzo[b]thiophene-3-carboxylic acid, 5-acetoxybenzo[b]thiophene-3-carboxylic acid, benzo[b]thiophene-3-carboxylic acid, and 5-benzosulfonyloxybenzo[b]thiophene-3-carboxylic acid, 5-methylbenzo[b]thiophene-3-carboxylic acid, 6-methylbenzo[b]thiophene-3-carboxylic acid, 5-methoxybenzo[b]thiophene-3-carboxylic acid, 6-methoxybenzo[b]thiophene-3-carboxylic acid. These carboxylic acids may have the substituents as defined above.

These carboxylic acids can be prepared in accordance with methods as described in Nippon Kagaku Zasshi Vol. 88, No. 7, 758-763 (1967), Nippon Kagaku Zasshi Vol. 86, No. 10, 1067-1072 (1965), J. Chem. Soc (c) 1899-1905 (1967), J. Heterocycle. Chem. Vol. 10 679-681 (1973), J. Heterocyclic Chem. Vol 19 1131-1136 (1982) and J. Med. Chem. Vol. 29 1637-1643 (1986).

The reactive derivative of carboxylic acid of the formula (III) means the corresponding acid halide (e.g., chloride, bromide, iodide), acid anhydride (e.g., mixed acid anhydride with formic acid or acetic acid), active ester (e.g., succinimide ester), and the like, and can generally be defined as acylating agents used for the acylation of amino group. For example, when an acid


halide is employed, the compound (III) is reacted with a thionyl halide (e.g., thionyl chloride), phosphorous halide (e.g., phosphorous trichloride, phosphorous pentachloride), oxalyl halide (e.g., oxalyl chloride), and the like, in accordance with known methods as described in the literatures (e.g., Shin-Jikken-Kagaku-Koza, Vol. 14, 1787 (1978); Synthesis 852-854 (1986); Shin-Jikken-Kagaku-Koza Vol. 22, 115 (1992)).

The reaction can be conducted under a condition generally used for the acylation of amino group. For example, in the case of condensation with the acid halide, the reaction is carried out in a solvent such as an ether solvent (e.g., diethyl ether, tetrahydrofuran, dioxane), benzene solvent (e.g., benzene, toluene, xylene), halogenated solvent (e.g., dichloromethane, dichloroethane, chloroform) as well as ethyl acetate, dimethylformamide, dimethyl sulfoxide, acetonitrile, and those aqueous solvents, or the like, if necessary, in the presence of a base (e.g., organic base such as triethylamine, pyridine, N,N-dimethylaminopyridine, N-methylmorpholine; inorganic base such as sodium hydroxide, potassium hydroxide, potassium carbonate, or the like) under cooling at room temperature or under heating, preferably at a temperature ranging from -20 °C to ice-cooling temperature, or from room temperature to a refluxing temperature of the reaction system, for a period of several min to several hr, preferably for 0.5 hr to 24 hr, particularly, for 1 hr to 12 hr. In the case of using the carboxylic acid in a free form without converting into the reactive derivatives, the reaction is conducted in the presence of a condensing agent (e.g., dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-methylaminopropyl)carbodiimide, N,N'-carbonyldiimidazole) usually used

in the condensation reaction.

The compound (I) of the present invention can be also prepared in accordance with a method as follows.

Process 2



wherein the Y ring, R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration.

(Step 1)

In this step, a compound of the formula (V) can be prepared by reacting an amino compound of the formula (IV) with the carboxylic acid of the formula (III) or its reactive derivative, this step can be prepared in accordance with the same process as process 1. Some of the amino compound of the formula (IV) is described that the process is disclosed in Chem. Pharm. Bull. Vol. 37, No. 6, 1524-1533 (1989).

(Step 2)

In this step, the compound of the formula (V) is oxidized into the aldehyde compound of the formula (VI). This step may be carried out with chromated oxidizing agents such as Jones' reagent, Collins' reagent,

pyridinium chlorochromate, pyridinium dichromate in a solvent such as chlorinated hydrocarbon (e.g., chloroform, dichloromethane), ether (e.g., ethyl ether, tetrahydrofuran), or acetone, benzene, and the like under cooling or at room temperature for several hours. This step may be also carried out with oxidizing agents in the combination of appropriate activator agents (e.g., trifluoroacetic anhydride, oxalyl chloride) and dimethyl sulfoxide, if necessary, in the presence of base (e.g., organic base such as triethylamine, diethylamine).

(Step 3)

In this step, the α -chain of the aldehyde compound of the formula (VI) is conducted into the compound of the formula (I). In this step, the compound of the formula (I) can be prepared by reacting the aldehyde compound of the formula (VI) with an ylide compound corresponding to the rest part of the α -chain in accordance with conditions of the Wittig reaction. Further, the ylide compound corresponding to the rest part of the α -chain can be synthesized by reacting triphenylphosphine with a corresponding halogenated alkanoic acid or ester derivative thereof in the presence of a base according to a known method.

In the reaction of the other reactive derivatives or free acid with the amine (II) or (IV), according to the property of each reactive derivatives or free acid, in accordance with a known method, the reaction conditions are determined. The reaction product can be purified in accordance with a conventional purification, such as the extraction with a solvent, chromatography, recrystallization, and the like.

The objective compound (I) in the present invention can be converted into a corresponding ester derivative, if desired. For example, the ester can be prepared by esterification the carboxylic acid in accordance with a known method. If desired, E isomer, Z isomer or the mixtures can be produced depending on the reaction conditions.

When using a compound (I) of the present invention in treatment, it can be formulated into ordinary formulations for oral and parenteral administration. A pharmaceutical composition containing a compound (I) of the present invention can be in the form for oral and parenteral administration. Specifically, it can be formulated into formulations for oral administration such as tablets, capsules, granules, powders, syrup, and the like; those for parenteral administration such as injectable solution or suspension for intravenous, intramuscular or subcutaneous injection, inhalant, eye drops, nasal drops, suppositories, or percutaneous formulations such as ointment.

In preparing the formulations, carriers, excipients, solvents, and bases known to one ordinary skilled in the art may be used. In case of tablets, they are prepared by compressing or fomulating an active ingredient together with auxiliary components. Examples of usable auxiliary components include pharmaceutically acceptable excipients such as binders (e.g., cornstarch), fillers (e.g., lactose, microcrystalline cellulose), disintegrants (e.g., starch sodium glycolate) or lubricants (e.g., magnesium stearate). Tablets may be coated appropriately. In the case of liquid formulations such as syrups, solutions, or suspensions, they may contain suspending agents (e.g., methyl cellulose), emulsifiers (e.g., lecithin), preservatives and the like. In the case of injectable

formulations, it may be in the form of solution or suspension, or oily or aqueous emulsion, which may contain suspension-stabilizing agent or dispensing agent, and the like. In the case of an inhalant, it is formulated into a liquid formulation applicable to an inhaler. In the case of eye drops, it is formulated into a solution or a suspension. Especially, in the case of nasal drug for treating nasal blockage, it can be used as a solution or suspension prepared by a conventional formulating method, or as a powder formulated using a powdering agent (e.g., hydroxypropyl cellulose, carbopole), which are administered into the nasal cavity. Alternatively, it can be used as an aerosol after filling into a special container together with a solvent of low boiling point.

Although an appropriate dosage of the compound (I) varies depending on the administration route, age, body weight, sex, or conditions of the patient, and the kind of drug(s) used together, if any, and should be determined by the physician in the end, in the case of oral administration, the daily dosage can generally be between about 0.01 - 100 mg, preferably about 0.01 - 10 mg, more preferably about 0.01 - 1 mg, per kg body weight. In the case of parenteral administration, the daily dosage can generally be between about 0.001 - 100 mg, preferably about 0.001 - 1 mg, more preferably about 0.001 - 0.1 mg, per kg body weight. The daily dosage can be administered in 1 - 4 divisions.

The following Examples are provided to further illustrate the present invention and are not to be construed as limiting the scope.

The abbreviation used throughout the examples in the present invention are shown as follows.

Me methyl


Ac acetyl

Ph phenyl

Reference 1

Preparation of 5-Benzenesulfonyloxybenzo[b]thiophene-3-carboxyl chloride

(3)



To a solution of 8.63 g (44.4 mmol) of 5-hydroxybenzo[b]thiophene-3-carboxylic acid (**1**) (J.Chem.Soc (C), 1899-1905 (1967), M.Martin-Smith et al.) in 160 ml of 80 % aqueous tetrahydrofuran and 44 ml of 1N sodium hydroxide was added 87 ml of 0.56N sodium hydroxide and 6.2 ml (48.4 mmol) of benzenesulfonylchloride simultaneously with keeping at pH 11-12 with stirring under ice-cooling. After the reaction completion, the mixture was diluted with water, alkalized and washed with toluene. The aqueous layer was weakly acidified with conc. hydrochloric acid under stirring. The precipitated crystals were filtered, washed with water, and dried to give 14.33 g of 5-benzenesulfonyloxybenzo[b]thiophene-3-carboxylic acid (**2**). mp 202-203 °C.

NMR δ (CDCl₃),300MHz

7.16 (1H, dd, J=2.7 and 9.0Hz), 7.55-7.61 (2H, m), 7.73 (1H, m), 7.81 (1H, d, J=9.0Hz), 7.90-7.94(2H,m),8.16(1H,d,J=2.7Hz),8.60(1H,s).

IR(Nujol): 3102, 2925, 2854, 2744, 2640, 2577, 1672, 1599, 1558, 1500, 1460, 1451 cm⁻¹

Elemental analysis (for $C_{15}H_{10}O_5S_2$)


Calcd. (%): C, 53.88; H, 3.01; S, 19.18

Found (%): C, 53.83; H, 3.03; S, 19.04

A mixture of 5.582 g (16.7 mmol) of the above obtained 5-benzenesulfonyloxybenzo[b]thiophene-3-carboxylic acid (2), a drop of dimethylformamide, 3.57 ml (50 mmol) of thionyl chloride and 22 ml of toluene was refluxed for 1.5 hours, and then concentrated under reduced pressure to give 5.89 g of the objective compound (3).

Reference 2

Preparation of 5-Acetoxybenzo[b]thiophene-3-carbonyl chloride (5)



A solution of 100 mg (0.3 mmol) of the above obtained 5-benzenesulfonyloxybenzo[b]thiophene-3-carboxylic acid (2) in 1.2 ml of 1N sodium hydroxide was allowed to stand for 8 hours at 40 °C. Hydrochloric acid (1N, 1.2 ml) was added thereto, and the precipitated crystals were filtered, washed with water, and dried to give 58 mg of 5-hydroxybenzo[b]thiophene-3-carboxylic acid (1). Yield 96.6 %. mp 262-263 °C.


A solution of 1,140 mg of the above obtained 5-

hydroxybenzo[b]thiophene-3-carboxylic acid (1) in 2 ml of acetic anhydride and 4 ml of pyridine was allowed to stand for 3 hours. After addition of water, the mixture was stirred for 1.5 hours under ice-cooling, and the precipitated crystals were filtered, washed with water, and dried to give 1,349mg of 5-acetoxybenzo[b]thiophene-3-carboxylic acid (4). Yield 97.3 %. mp 239-240 °C.

A mixture of 1,349 mg of the above obtained 5-acetoxybenzo[b]thiophene-3-carboxylic acid (4), a drop of dimethylformamide, 1.22 ml of (17.13 mmol) of thionyl chloride and 25 ml of toluene was refluxed for 1.5 hours, and then concentrated under reduced pressure to give 1,454 mg of the objective compound (5).

Reference 3

Preparation of (1R, 2S, 3S, 5S)-2-(2-Amino-6,6-dimethylbicyclo[3.1.1]hept-3-yl)ethanol (IVA-b-1) and (1R, 2R, 3S, 5S)-2-(2-Amino-6,6-dimethylbicyclo[3.1.1]hept-3-yl)ethanol (IVA-c-1)



The compound (6) (Chem. Pharm. Bull. Vol.37, No.6 1524-1533 (1989)) was reduced with sodium according to the method described in the above literature, and the compound (IVA-a-1) was removed by filtration as the benzoic acid salt. The mother liquor (79 g) was suspended in 150ml of ethyl acetate, added 260 ml of 1N-hydrochloric acid, and stirred. The aqueous

layer separated from the two layers was basified with 65 ml of 4N-sodium hydroxide, and extracted with ethyl acetate. The organic layer was washed with water, and dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The obtained oily residue (6.7 g of 30 g) was dissolved in 40 ml of 90 % methanol, adsorbed by 500 ml of an ion-exchange resin, Amberlite CG-50 (NH₄⁺)type I, and eluted with 2.2 L of water and 1N-2.2 L of aqueous ammonia by a gradient method.

One fraction: 300ml. Each fraction was checked by thin-layer chromatography (the developing solvent ; chloroform: methanol: conc. aqueous ammonia= 90: 10: 1). The fractions 3-8 were collected, and concentrated under reduced pressure. The residue was crystallized from hexane; recrystallization afforded 538 mg of needles.

mp 117-118 °C.

NMR δ (CDCl₃), 300MHz

1.01 and 1.21 (each 3H, each s), 1.34 (1H, d, J=9.9Hz), 1.52-1.66 (2H,m), 1.90-2.07 (4H,m), 2.18 (1H, m), 2.48 (1H, m), 3.12 (3H, bs), 3.49 (1H, dd, J=3.9 and 9.6Hz), 3.61 (1H, dt, J=2.4 and 10.5Hz), 3.84 (1H, ddd, J=3.3, 4.8 and 10.5Hz).

IR(Nujol): 3391, 3293, 3108, 2989, 2923, 2869, 2784, 2722, 2521, 1601, 1489, 1466 cm⁻¹

[α]_D²³-2.5° (c=1.02, CH₃OH)

Elemental analysis for (C₁₁H₂₁NO)

Calcd.: (%): C, 72.08; H, 11.55; N, 7.64

Found: (%): C, 72.04; H, 11.58; N, 7.58

By means of X-ray crystal analysis, the structural formula was identified as that of (1R, 2R, 3S, 5S)-2-(2-amino-6,6-dimethylbicyclo[3.1.1]hept-3-yl)ethanol (IVA-c-1). The mother liquor (2.9 g) after the recrystallization from hexane was dissolved in 15 ml of ethyl acetate, to which was added a solution of 30 ml of ethyl acetate containing 1.93 g of benzoic acid. The precipitated crystals were filtered to give 2.93 g of the benzoic acid salt of the compound (IVA-a-1).
mp 182-183 °C.

The fractions 10-17 were collected and concentrated under reduced pressure. To a solution of 2.66 g of the residue in 15 ml of ethyl acetate was added 11 ml of ethyl acetate containing 1.77 g of benzoic acid. The precipitated crystals were filtered to give 4.08 g of needles.
mp 160-161 °C.

NMR δ (CDCl₃), 300MHz

0.61 and 1.06 (each 3H, each s), 1.36 (1H, m), 1.53-1.65 (2H, m), 1.75-1.88 (2H, m), 1.95-2.04 (4H, m), 3.18 (1H, d, J=6.3Hz), 3.58 (1H, dt, J=3.0 and 10.8Hz), 3.81 (1H, m), 5.65 (4H, bs), 7.33-7.42 (3H, m), 7.98-8.01 (2H, m).

IR(Nujol): 3320, 2922, 2854, 2140, 1628, 1589, 1739, 1459, 1389 cm⁻¹

[α]_D²³ -31.8° (c=1.01, CH₃OH)

Elemental analysis (for C₁₈H₂₇NO₃)

Calcd.: (%): C, 70.79; H, 8.91; N, 4.59


Found: (%): C, 70.63; H, 8.86; N, 4.58

By means of X-ray crystal analysis, the structural formula was identified as that of (1R, 2S, 3S, 5S)-2-(2-amino-6,6-

dimethylbicyclo[3.1.1]hept-3-yl)ethanol (IVA-b-1).

Example 1

Preparation of Sodium (5Z)-7-((1R,2R,3S,5S)-2-(5-hydroxybenzo[b]thiophen-3-yl-carbonylamino)-6,6-dimethylbicyclo[3.1.1]hept-3-yl)-5-heptenoate (IA-a-6)



(Step 1)

To a solution of 1,450 mg (5.2 mmol) of a compound (IIA-a-1) (Japanese Patent Publication (Kokoku) No. 23170/1994) in 25 ml of tetrahydrofuran were added 2.6 ml (18.7 mmol) of triethylamine and 1,454 mg (1.1 mmol) of 5-acetoxybenzo[b]thiophene-3-carbonyl chloride (5) obtained by the reference 2. After stirring for 1.5 hours, the mixture was diluted with water, and extracted with toluene. The organic layer was washed with dilute hydrochloric acid and water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was chromatographed on silica gel (toluene:ethyl acetate=9:1) to give 2,481 mg of the compound (IA-a-10). Yield 96.1 %.

$[\alpha]_D^{23} = +48.0^\circ$ (c=1.01%, CH₃OH)

Elementary Analysis (for $C_{28}H_{35}NO_5 \cdot 0.1H_2O$)

Calcd.(%): C, 67.34; H, 7.10; N, 2.80; S, 6.42

Found(%): C, 67.23; H, 7.12; N, 2.86; S, 6.59

(Step 2)

To a solution of 2,357 mg (4.73 mmol) of the above obtained compound (IA-a-10) in 25 ml of methanol was added 4.1 ml (16.4 mmol) of 4N-sodium hydroxide. After stirring for 6 hours, the mixture was neutralized with 17 ml of 1N-hydrochloric acid, diluted with water, and extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The residue was recrystallized from ethyl acetate/n-hexane to give 1,859 mg of the compound (IA-a-5) as prisms. Yield 86.5 %.

mp 142-143 °C.

$[\alpha]_D^{23} = +47.6^\circ$ (c=1.01%, CH₃OH)

Elementary Analysis (for $C_{25}H_{31}NO_4S$)

Calcd.(%): C, 68.00; H, 7.08; N, 3.17; S, 7.26

Found(%): C, 67.93; H, 7.08; N, 3.19; S, 7.24

(Step 3)

To a solution of 203 mg (0.46 mmol) of the above obtained compound (IA-a-5) in 3 ml of methanol was added 0.42 ml (0.42 mmol) of 1N-sodium hydroxide, and the mixture was concentrated under reduced pressure. The residue was dissolved in a small quantity of ethyl acetate, and diluted with n-hexane. The insoluble material was dissolved in methanol, and concentrated under reduced pressure to give 210 mg of the objective

compound (IA-a-6). Yield 98.5 %.

$[\alpha]_D^{25} = +38.9^\circ$ (c=1.00%, CH₃OH)


Elementary Analysis (for C₂₅H₃₀NO₄SNa · 0.5H₂O)

Calcd. (%): C, 63.54; H, 6.61; N, 2.96; S, 6.78; Na, 4.86

Found (%): C, 63.40; H, 6.69; N, 3.13; S, 6.73; Na, 4.68

Example 2

Preparation of (5Z)-7-[(1R,2S,3R,5S)-2-(5-hydroxybenzo[b]thiophen-3-yl-carboxylamino)-6,6-dimethyl-bicyclo[3.1.1]hept-3-yl]-5-heptenoic acid (IA-b-1)



(Step 1)

To a suspension of 916 mg (3 mmol) of (1R, 2S, 3S, 5S)-2-(2-amino-6,6-dimethylbicyclo[3.1.1]hept-3-yl)ethanol benzoic acid salt in 3 ml of water was added 3.1 ml of 1N hydrochloric acid. The precipitated benzoic acid was extracted with ethyl acetate. The aqueous layer was adjusted at pH 10.5 with 700 mg of anhydrous sodium carbonate, to which was dropwise added a solution of 1.06 g (3 mmol) of 5-benzenesulfonyloxybenzo[b]thiophene-3-

carbonyl chloride (3) in 6 ml of tetrahydrofuran. After 1.5 hours, the mixture was diluted with water and extracted with toluene. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The thus-obtained residue (1.5 g) was chromatographed on silica gel (hexane: ethyl acetate=1:1) to give 1.497 g of the compound (VA-b-1). Yield 99.8 %.

$[\alpha]_D^{23} -31.1^\circ$ (c=1.00, CH₃OH)

Elemental analysis (for C₂₆H₂₉NO₅S₂ · 0.2H₂O)

Calcd. (%): C, 62.05; H, 5.89; N, 2.78; S, 12.74

Found (%): C, 62.03; H, 5.93; N, 2.79; S, 12.72

(Step 2)

A solution of 0.61 ml (8.6 mmol) of dimethylsulfoxide in 9.7 ml of 1,2-dimethoxyethane was cooled at -60°C, to which was dropwise added 0.37 ml (4.3 mmol) of oxalyl chloride. After 15 minutes, a solution of 1.427 g (2.9 mmol) of the above obtained compound (VA-b-1) in 11 ml of 1,2-dimethoxyethane was added thereto. After stirring for 30 minutes, 1.2 ml of triethylamine was added, and the mixture was stirred for 30 minutes, and warmed up gradually to room temperature. The mixture was diluted with water and extracted with toluene. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The thus-obtained residue was chromatographed on silica gel (hexane: ethyl acetate=6:4) to give 1.338 g of the compound (VIA-b-1). Yield 94.1 %.

$[\alpha]_D^{24} -29.1^\circ$ (c=1.01, CH₃OH)

Elemental analysis (for $C_{26}H_{27}NO_5S_2 \cdot 0.4H_2O$)

Calcd. (%): C,61.85;H,5.55;N,2.77;S,12.70

Found (%):C,61.92;H,5.60;N,2.79;S,12.88

(Step 3)

A suspension of 1.72 g (3.9 mmol) of 4-carboxybutyltriphenylphosphonium bromide and 1.016 g (9 mmol) of potassium t-butoxide in 9 ml of tetrahydrofuran was stirred for 1 hour under ice-cooling. To the mixture was added a solution of 1.288 g (2.6 mmol) of the above obtained compound (VIA-b-1) in 4 ml of tetrahydrofuran over 6 minutes, and the mixture was stirred at the same temperature for 2 hours. The mixture was diluted with 15 ml of water, acidified to pH 10.5 with 1N hydrochloric acid, and washed with 15 ml of toluene twice. The aqueous layer was acidified with 1N hydrochloric acid at pH 8.0, added 1.15 g (10.4 mmol) of anhydrous calcium chloride, and extracted with 15 ml of ethyl acetate twice. The organic layer was diluted with 16 ml of water, acidified with 1N hydrochloric acid at pH 2-3, and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 1.44 g of the compound (IA-b-1'). Yield 95.5 %.

The compound was used for the next step without further purification.

(Step 4)

To a solution of 1.44 g (2.6 mmol) of the above obtained compound (IA-b-1') in 2.8 ml of dimethylsulfoxide was added 3.9 ml of 4N sodium hydroxide, and the mixture was stirred at 55 °C for 3 hours. The mixture was diluted

with water and washed with 15 ml of toluene twice. The aqueous layer was acidified with 1N hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 1.097 g of the compound (IA-b-1). Yield 95.9 %.

$[\alpha]_D^{25} +43.0^\circ$ (c=1.01, CH₃OH)

Elemental analysis (for C₂₅H₃₁NO₄S · 0.2H₂O)

Calcd.(%): C,67.45;H,7.11;N,3.15;S,7.20

Found (%): C,67.51;H,7.15;N,3.38;S,6.96

Example 3

Preparation of (5E)-7-[(1R,2R,3S,5S)-2-(5-hydroxybenzo[b]thiophen-3-yl-carbonylamino)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoic acid (IA-a-17)



A solution of 11.04 g (25 mmol) of (5Z)-7-[(1R,2R,3S,5S)-2-(5-hydroxybenzo[b]thiophen-3-yl-carbonylamino)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5-heptenoic acid (IA-a-5), 4.32 g (18.8 mmol) of 1-methyltetrazol-5-yl disulfide (J. Org. Chem., 50, 2794-2796 (1985), M.Narisada, Y.Terui, M.Yamakawa, F.Watanebe, M.Ohtani, and H.Miyazaki et al.) and 2.84 g (17.3 mmol) of 2,2'-azobisisobutyronitrile in 1.1 L of benzene was refluxed with stirring for 8 hours. The mixture was extracted with 400

ml of 0.4 N sodium hydroxide twice. The aqueous layer was acidified with hydrochloric acid, and the precipitate was collected by filtration. The precipitate (11.08 g) was chromatographed on silica gel (chloroform : methanol = 10 : 1) to give 6.93 g of the compound. The obtained compound was dissolved in 69 ml of dimethoxyethane, to which was added 2.15 g of 4-methoxybenzylamine, and successively diluted with 120ml of ether under ice-cooling. The precipitate was filtered to give 7.45 g of the crystalline product, which was recrystallized from isopropyl alcohol/ ethyl acetate/ ether (= 2/10/5) for purification.

mp 108-111 °C.

$[\alpha]_D^{23} + 18.9^\circ$ (c=1.00, CH₃OH)

The purity of the isomer of the 4-methoxybenzylamine salt was analyzed by HPLC. Result: (E-isomer) : (Z-isomer) = 98.4 : 1.6.

[HPLC condition] Column: YMC-pack AM-303-10(10 μ m.120A.ODS) (4.6mm Φ X250mm); flow rate:1ml/min; detection:UV 254nm; mobile phase: acetic acid/water/acetonitrile=0.1/52/48; retention time: (E-isomer) 21 minutes, (Z-isomer) 23 minutes.

The purified 4-methoxybenzylamine salt (1.6 g) was suspended in 25 ml of water, acidified with 25 ml of 1N-hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 1.21 g of the compound (IA-a-17).

$[\alpha]_D^{24} + 14.4^\circ$ (c=1.01, CH₃OH)


Elemental analysis (for C₂₅H₃₁NO₄S · 0.1H₂O)

Calcd.(%): C,67.72;H,7.09;N,3.16;S,7.23

Found(%): C,67.59;H,7.26;N,3.35;S,7.39


Compounds and physical constants obtained in the same manner as the above Examples are shown in the following table 1 -table 14.

Table 1




| Compd.No. | X | Z | Compd.No. | X | Z |
|-----------|----|---|-----------|-----------------|---|
| IA-a-1 | H | | IA-a-9 | H | |
| IA-a-2 | H | | IA-a-10 | CH ₃ | |
| IA-a-3 | H | | IA-a-11 | H | |
| IA-a-4 | H | | IA-a-12 | H | |
| IA-a-5 | H | | IA-a-13 | H | |
| IA-a-6 | Na | | IA-a-14 | H | |
| IA-a-7 | H | | IA-a-15 | H | |
| IA-a-8 | H | | IA-a-16 | H | |

Table 2



| Compd.No. | | Compd.No. | |
|-----------|--|-----------|--|
| IA-a-17 | | IA-b-3 | |
| IA-c-1 | | IA-d-1 | |
| IA-c-2 | | IA-d-2 | |
| IA-c-3 | | IA-d-3 | |
| IA-c-4 | | IA-b'-1 | |
| IA-b-1 | | IA-b'-2 | |
| IA-b-2 | | IA-b'-3 | |


Table 3




Compd.No.

Compd.No.


IB-b'-1




IB-b'-4




IB-b'-2




IB-b'-5




IB-b'-3




IB-a'-1




IB-a'-4



IB-a'-2



IB-a'-5



IB-a'-3





Table 4



Compd.No.

Compd.No.













Table 5









**Compd.No.**

Table 6




| Compd.No. | Chemical Structure | Compd.No. | Chemical Structure |
|-----------|--------------------|-----------|--------------------|
| IB-a-1 | | IB-a-4 | |
| IB-a-2 | | IB-a-5 | |
| IB-a-3 | | | |
| IB-b-1 | | IB-b-4 | |
| IB-b-2 | | IB-b-5 | |
| IB-b-3 | | | |

Table 7



| Compd.No. | | Compd.No. | |
|-----------|--|-----------|--|
| IB-c-1 | | IB-c-4 | |
| IB-c-2 | | IB-c-5 | |
| IB-c-3 | | | |
| IB-d-1 | | IB-d-4 | |
| IB-d-2 | | IB-d-5 | |
| IB-d-3 | | | |


Table 8




Compd.No.

Compd.No.


IB-c'-1




IB-c'-4




IB-c'-2




IB-c'-5




IB-c'-3




IB-d'-1




IB-d'-4



IB-d'-2



IB-d'-5



IB-d'-3




Table 9

| Compd. No. | Physical constant |
|---------------|--|
| IA-a-1 | <p>NMR δ (CDCl₃ ppm), 300MHz 0.97 (1H,d,J=10.2Hz), 1.16 and 1.25 (each 3H,each s), 1.53-2.46 (14H,m), 4.28 (1H,m), 5.36-5.53 (2H,m), 6.34 (1H,d,J=8.7Hz), 7.26 (1H,t,7.8Hz), 7.56 (1H,dd,J=0.9 and 7.8Hz), 7.77 (1H,m), 7.80 (1H,d,J=0.6Hz). IR (CHCl₃): 3509, 3446, 3429, 1738, 1708, 1651, 1548, 1525, 1498cm⁻¹. [α]D +53.4° (CH₃OH, c=1.01,25°C).</p> |
| IA-a-2 | <p>0.99 (1H,d,J=10.2Hz), 1.13 and 1.26 (each 3H,each,s), 1.54-2.51 (14H,m), 4.32 (1H,m), 5.37-5.54 (2H,m), 6.17 (1H,d,J=8.4Hz), 7.49 (1H,dd,J=1.8 and 8.7Hz), 7.72 (1H,d,J=8.7Hz), 7.81 (1H,s), 8.54 (1H,d,J=1.8Hz). IR (CHCl₃): 3517, 3443, 2665, 1708, 1654, 1514cm⁻¹. [α]D +39.5° (CH₃OH, c=1.00,26°C).</p> |
| IA-a-3 | <p>0.98 (1H,d,J=10.2Hz), 1.11 and 1.24 (each 3H,each s), 1.53-2.50 (14H,m), 4.32 (1H,m), 5.36-5.54 (2H,m), 6.18 (1H,d,J=8.7Hz), 7.54 (1H,dd,J=1.8 and 8.7Hz), 7.75 (1H,s), 7.98 (1H,d,J=7.5Hz), 8.23 (1H,d,J=8.7Hz). IR (CHCl₃): 3517, 3443, 3095, 1708, 1654, 1585,1512cm⁻¹. [α]D +49.4° (CH₃OH, c=1.01,23°C).</p> |
| IA-a-4 | <p>0.99 (1H,d,J=10.2Hz), 1.12 and 1.25 (each 3H,each s), 1.54-2.51 (14H,m), 4.32 (1H,m), 5.36-5.54 (2H,m), 6.19 (1H,d,J=9.0Hz), 7.34 (1H,dd,J=7.8 and 8.4Hz), 7.55 (1H,m), 7.86 (1H,s), 8.33 (1H,dd,J=0.9 and 8.4Hz). IR (CHCl₃): 3517, 3442, 3095, 2667, 1708, 1653, 1545, 1515 cm⁻¹. [α]D +54.6° (CH₃OH, c=1.01,23°C).</p> |

Table 10

| Compd. No. | Physical constant |
|---------------|--|
| IA-a-5 | 1.02 (1H,d,J=10.2Hz), 1.12 and 1.24 (each 3H,each s), 1.56-2.55 (14H,m), 4.29 (1H,m), 5.32-5.51 (2H,m), 6.20 (1H,d,J=9.3Hz), 7.01 (1H,dd,J=2.4 and 9.0Hz), 7.66 (1H,d,J=9.0Hz), 7.69 (1H,s), 8.03 (1H,d,J=2.4Hz). IR (CHCl ₃): 3600, 3440, 3226, 1707, 1638, 1602, 1516 cm ⁻¹ . [α] _D +47.6° (CH ₃ OH, c=1.00, 23°C). mp 142-143°C. |
| IA-a-6 | (CD ₃ OD) 0.97 (1H,d,J=9.9Hz), 1.16 and 1.25 (each 3H,each s), 1.55-2.43 (14H,m), 4.18 (1H,m), 5.41-5.53 (2H,m), 6.93 (1H,dd,J=0.6 and 8.7Hz), 7.68 (1H,dd,0.6 and 8.7Hz), 7.71 (1H,m), 8.01 (1H,s). IR (KBr): 3436, 2621, 1637, 1600, 1557, 1520, 1434cm ⁻¹ . [α] _D +38.9° (CH ₃ OH, c=1.00, 25°C). |
| IA-a-7 | 0.97 (1H,d,J=10.2Hz), 1.10 and 1.23 (each 3H,each s), 1.54-2.52 (14H,m), 4.32 (1H,m), 5.35-5.54 (2H,m), 6.26 (1H,d,J=8.7Hz), 6.98 (1H,dd,J=2.4 and 9.0Hz), 7.26 (1H,m), 7.58 (1H,s), 8.07 (1H,d,J=9.0Hz). IR (CHCl ₃): 3592, 3439, 3223, 3102, 1708, 1639, 1604, 1518cm ⁻¹ . [α] _D +51.5° (CH ₃ OH, c=1.01, 25°C). |
| IA-a-8 | 0.96 (1H,d,J=10.2Hz), 1.11 and 1.24 (each 3H,each s), 1.54-2.53 (14H,m), 4.34 (1H,m), 5.35-5.53 (2H,m), 6.31 (1H,d,J=9.0Hz), 6.79 (1H,d,J=7.5Hz), 7.25 (1H,dd,J=7.5 and 8.4Hz), 7.74 (1H,d,J=8.4Hz), 7.86 (1H,s). IR (CHCl ₃): 3586, 3437, 3104, 1708, 1638, 1568, 1522, 1501, 1471 cm ⁻¹ . [α] _D +57.1° (CH ₃ OH, c=1.01, 25°C). |

Table 11

| Compd. No. | Physical constant |
|---------------|--|
| IA-a-9 | 0.98 (1H,d,J=10.2Hz), 1.12 and 1.25 (each 3H,each s), 1.54-2.51 (14H,m), 2.33 (3H,s), 4.30 (1H,m), 5.36-5.54 (2H,m), 6.17 (1H,d,J=8.7Hz), 7.15 (1H,dd,J=2.1 and 9.0Hz), 7.83 (1H,d,J=9.0Hz), 7.84 (1H,s), 8.11 (1H,d,J=2.1Hz). IR (CHCl ₃): 3510, 3443, 2665, 1758, 1708, 1653, 1514cm ⁻¹ . [α] _D +47.8° (CH ₃ OH, c=1.00,25°C). |
| IA-a-17 | NMR δ (CDCl ₃),300MHz 1.00(1H,d,J=10.5Hz),1.12 and 1.23(each 3H,each s),1.50-1.66(3H,m), 1.84-2.03(4H,m),2.17-2.40(7H,m),4.33(1H,m), 5.42- 5.45(2H,m),6.16(1H,d,J=9.0Hz),7.01(1H,dd,J=2.4 and 8.7Hz),7.66(1H,d,J=8.7Hz),7.69(1H,s), 8.04(1H,d,J=2.4Hz). IR(CHCl ₃):3441,3237,3035,3009,2992,2924,2870,1708,1637 ,1601,1516,1436 cm ⁻¹ [α] _D ²⁴ +14.4° (c=1.01%,CH ₃ OH) |
| IA-c-1 | 1.09 and 1.25(each 3H,each s),1.50(1H,d,J=9.9Hz),1.52-1.69(3H,m), 2.02- 2.30(10H,m),2.49(1H,m), 4.89(1H,dt, J=3.9 and 9.6Hz), 5.30-5.54(2H,m), 6.49(1H,d,J=9.6Hz), 7.03(1H,dd,J=2.4 and 8.7Hz), 7.67(1H,d,J=8.7Hz), 7.74(1H,s),8.00(1H,d,J=2.4Hz). IR(CHCl ₃):3464,3225,3022,3016,2924,2870,1707,1639, 1602,1519,1479,1459,1437 cm ⁻¹ [α] _D ²⁵ -57.1° (c=1.00%,CH ₃ OH) |

Table 12

| Compd. No. | Physical constant |
|---------------|---|
| IA-c-2 | <p>1.08 and 1.25(each and each s), 1.49-1.62(4H,m), 1.84-2.10(5H,m), 2.14-2.30(5H,m), 2.56(1H,m), 4.89(1H,dt,J=3.3 and 9.9Hz), 5.25-5.40(2H,m), 6.50(1H,d,J=10.2Hz), 7.04(1H,dd,J=2.4 and 9.0Hz), 7.68(1H,d,J=9.0Hz), 7.69(1H,s), 8.09(1H,d,J=2.4Hz).</p> <p>IR(Nujol): 3460, 3178, 2927, 2854, 2726, 2680, 1702, 1639, 1600, 1517 cm^{-1} $[\alpha]_{\text{D}}^{24}$-34.6° (c=1.01%, CH₃OH) mp 166-167°C</p> |
| IA-b-1 | <p>1.00 and 1.23(each and each s), 1.22-1.40(6H,m), 1.92-2.25(8H,m), 2.47(1H,m), 4.32(1H,t,J=8.6Hz), 5.26-5.50(2H,m), 6.15(1H,d,J=9.0Hz), 7.02(1H,dd,J=2.4 and 8.7Hz), 7.65(1H,d,J=8.7Hz), 7.73(1H,s), 8.07(1H,d,J=2.4Hz).</p> <p>IR(CHCl₃): 3423, 3223, 3033, 3016, 2925, 2870, 1707, 1638, 1601, 1436 cm^{-1} $[\alpha]_{\text{D}}^{25}$-43.0° (c=1.01%, CH₃OH)</p> |
| IA-d-1 | <p>1.06 and 1.23(each and each s), 1.07(1H,d,J=9.9Hz), 1.51-1.68(3H,m), 1.80-2.60(11H,m), 4.81(1H,dt,J=2.7 and 9.9Hz), 5.29-5.51(2H,m), 6.32(1H,d,J=9.6Hz), 7.02(1H,dd,J=2.4 and 9.0Hz), 7.66(1H,d,J=9.0Hz), 7.77(1H,s), 7.99(1H,d,J=2.4Hz).</p> <p>IR(CHCl₃): 3394, 3163, 2926, 2854, 2681, 2609, 1698, 1636, 1599, 1529, 1458, 1437 cm^{-1} $[\alpha]_{\text{D}}^{25}$+77.3° (c=1.01%, CH₃OH) mp 148-149°C</p> |

Table 13

| Compd. No. | Physical constant |
|---------------|---|
| IA-b'-1 | 1.02(1H,d,J=10.2Hz),1.13 and 1.24(each 3H,each s),1.56-2.55(14H,m), 4.29(1H,m),5.35-5.51(2H,m),6.20(1H,d,J=9.3Hz),7.01(1H,dd,J=2.4 and 9.0Hz),7.65(1H,d,J=9.0Hz),7.69(1H,s),8.00(1H,d,J=2.4Hz). IR(CHCl ₃):3440,3226,1708,1637,1602,1516 cm ⁻¹ [α] _D ²⁵ -49.9° (c=1.01%,CH ₃ OH) mp 143-144°C |
| IB-b'-1 | 0.87 and 1.24(each 3H,each s),1.51(1H,d,J=10.5Hz),1.60-2.61(14H,m),4.24(1H,m),5.32-5.45(2H,m), 6.12(1H,d,J=9.0 Hz), 7.37-7.48(2H,m),7.85-7.88(2H,m), 8.33(1H,d,J=7.8Hz) IR(CHCl ₃):3429,3067,3023,3014,2923,2871,1708,1652, 1556,1516, 1494cm ⁻¹ [α] _D ²⁵ -23.0° (c=1.00%,CH ₃ OH) |
| IB-b'-2 | 1.11 and 1.24(each 3H,each s),1.50(1H,d,J=10.8Hz),1.59-2.60(14H,m), 4.2(1H,m),5.32-5.45(2H,m),6.09(1H,d, J=8.4Hz), 7.16(1H,ddd,J=2.4,9.0 and 10.2Hz),7.77(1H,dd, J=4.8 and 9.0Hz),7.93(1H,s),8.09(1H,dd,J=2.4 and 0.2Hz) IR(CHCl ₃):3429,3095,3030,3015,2923,2871,1708,1653, 1603,1566,1517,1432cm ⁻¹ [α] _D ²⁵ -22.4° (c=1.01%,CH ₃ OH) |
| IB-b'-3 | 0.86 and 1.23(each 3H,each s),1.49-2.58(15H,m),4.24 (1H,m),5.25-5.40(2H,m),6.18(1H,d,J=9.0Hz), 7.03(1H,dd, J=2.4 and 8.7Hz),7.66(1H,d,J=8.7Hz),7.77(1H,s), 8.06(1H,d,J=2.4Hz). IR(CHCl ₃):3425,3237,3029,3021,3017,2924,2871,1707, 1637,1519,1457,1437cm ⁻¹ [α] _D ²⁵ -18.7° (c=1.00%,CH ₃ OH) |

Table 14

| Compd. No. | Physical constant |
|---------------|---|
| IB-a'-1 | 0.91(1H,d,J=10.2Hz), 1.13 and 1.25(each 3H,each s), 1.60-1.88(3H,m), 2.01- 2.50(10H,m), 2.79(1H,t,J=11.6Hz), 4.54(1H,m), 5.31- 5.50(2H,m), 6.10(1H,d,J=8.4Hz), 7.37-7.48(2H,m), 7.85-7.88(2H,m), 8.33(1H,d,J=7.5Hz). IR(CHCl ₃): 3429, 3065, 3023, 3015, 2923, 2872, 1708, 1651, 1556, 1516, 1493cm ⁻¹ [α] _D ²⁵ +26.5° (c=1.01%, CH ₃ OH) |
| IB-a'-2 | 0.91(1H,d,J=10.2Hz), 1.12 and 1.25(each 3H,each s), 1.60-1.90(3H,m), 2.01-2.50(10H,m), 2.78(1H,t,J=12.2Hz), 4.52(1H,m), 5.30-5.50(2H,m), 6.08(1H,d,J=8.4Hz), 7.16(1H,dt,J=2.7 and 8.7Hz), 7.77(1H,dd,J=4.5 and 8.7Hz), 7.91(1H,s), 8.09(1H,dd,J=2.7 and 9.9Hz). IR(CHCl ₃): 3430, 3095, 3024, 3015, 2923, 2872, 1708, 1652, 1603, 1565, 1517, 1433cm ⁻¹ [α] _D ²⁵ +25.8° (c=1.00%, CH ₃ OH) |
| IB-a'-3 | 0.88(1H,d,J=9.9Hz), 1.11 and 1.26(each 3H,each s), 1.50-1.90(3H,m), 2.00-2.23(8H,m), 2.40-2.50(2H,m), 2.83(1H,t,J=12.0Hz), 4.55(1H,m), 5.24-5.44(2H,m), 6.11(1H,d,J=9.0Hz), 7.02(1H,dd,J=2.4 and 8.4Hz), 7.67(1H,d,J=8.4Hz), 7.75(1H,s), 8.12(1H,d,J=2.4Hz). IR(CHCl ₃): 3425, 3222, 3028, 3022, 3015, 2923, 2872, 1707, 1637, 1601, 1519, 1456, 1437cm ⁻¹ [α] _D ²⁵ +19.3° (c=1.00%, CH ₃ OH) |

The compounds prepared in Examples above were tested for determining the in vivo and in vitro activities according to the method as shown in Experimental examples below.

Experiment 1 Binding to PGD₂ Receptor

Materials and Methods

(1) Preparation of Human Platelet Membrane Fraction

Blood sample was obtained using a plastic syringe containing 3.8 % sodium citrate from the vein of healthy volunteers (adult male and female), put into a plastic test tube and mixed gently by rotation. The sample was then centrifuged at 1800 rpm, 10 min at room temperature, and the supernatant containing PRP (platelet-rich plasma) was collected. The PRP was re-centrifuged at 2300 rpm, 22 min at room temperature to obtain platelets. The platelets were homogenized using a homogenizer (Ultra-Turrax) followed by centrifugation 3 times at 20,000 rpm, 10 min at 4°C to obtain a platelet membrane fraction. After protein determination, the membrane fraction was adjusted to 2 mg/ml and preserved in a refrigerator at -80°C until use.

(2) Binding to PGD₂ Receptor

To a binding-reaction solution (50 mM Tris/HCl, pH 7.4, 5 mM MgCl₂) (0.2 ml) were added the human platelet membrane fraction (0.1 mg) and 5 nM [³H]PGD₂ (115Ci/mmol), and reacted at 4°C for 90 min. After the reaction completed, the reaction mixture was filtered through a glass fiber filter paper, washed several times with cooled saline, and measured the radioactivity retained on the filter paper. The specific binding was calculated by subtracting the non-specific binding (the binding in the presence of 10 μM PGD₂) from the

total binding. The inhibitory activity of each compound was expressed as the concentration required for 50 % inhibition (IC_{50}), which was determined by depicting a substitution curve by plotting the binding ratio (%) in the presence of each compound, where the binding ratio in the absence of a test compound is 100 %. The results are shown in Table 15.

Table 15

| Compd.No. | IC_{50} (n M) |
|-----------|-----------------|
| IA-a-2 | 3.3 |
| IA-a-5 | 0.4 |
| IA-a-7 | 1.3 |
| IA-a-9 | 6.5 |
| IA-a-17 | 1.2 |
| IA-c-1 | 28 |
| IA-c-2 | 1 |
| IB-a'-2 | 37 |

Experiment 2 Evaluation of Antagonistic Activity Against PGD_2 Receptor

Using Human Platelet

Peripheral blood was obtained from a healthy volunteer using a syringe in which 1/9 volume of citric acid/dextrose solution has been previously added. The syringe was subjected to centrifugation at 180 g for 10 min to obtain the supernatant (PRP: platelet rich plasma). The resultant PRP was washed 3 times with a washing buffer and the number of platelet was counted with a micro cell counter. A suspension adjusted to contain platelet at a final concentration of 5×10^8 /ml was warmed at 37°C , and then subjected to the pre-treatment with 3-isobutyl-1-methylxanthine (0.5mM) for 5 min. To the suspension was added a test compound diluted at various concentration. Ten-minute later, the reaction was induced by the addition of $0.1 \mu\text{M}$ PGD_2 and, 2-minute later, stopped by the addition of hydrochloric acid. The platelet was destroyed with an ultrasonic

homogenizer. After centrifugation, the cAMP in the supernatant was determined by radioimmunoassay. PGD₂ receptor antagonism of a drug was evaluated as follows. The inhibition rate regarding cAMP increased by the addition of PGD₂ was determined at individual concentration, and then the concentration of the drug required for 50 % inhibition (IC₅₀) was calculated. The results are shown in Table 16.

Table 16

| Compd.No. | I C ₅₀ (n M) |
|-----------|-------------------------|
| IA-a-5 | 1.3 |
| IA-a-7 | 2.8 |
| IA-a-9 | 0.21 |
| IA-a-17 | 28 |
| IA-c-1 | 55 |
| IA-c-2 | 61 |
| IB-b'-3 | 57 |
| IB-a'-1 | 41 |

Experiment 3 Experiment Using Nasal Blockage Model

The method used for measuring the intranasal pressure for evaluating the anti-nasal blockage using guinea pigs is described below.

A 1% ovalbumin (OVA) solution was treated with an ultrasonic nebulizer to obtain an aerosol. Hartley male guinea pig was sensitized by inhaling twice the aerosol for 10 min at one-week interval. Seven-day after the sensitization, the guinea pig was exposed to an antigen to initiate the reaction. Briefly, the trachea was incised under the anesthesia with pentobarbital (30 mg/kg, i.p.) and cannulas were inserted into the trachea at the pulmonary and nasal cavity sides. The canal inserted at the pulmonary side was connected with an artificial respirator that provides 4 ml air 60 times/min. After arresting the spontaneous respiration of the guinea pig with Gallamin (2 mg/kg, i.v.), air was supplied to

the snout side with an artificial respirator at the frequency of 70 times/min, and the flow rate of 4 ml air/time, and the atmospheric pressure required for the aeration was measured by the use of a transducer fitted at the branch. The measurement was used as a parameter of the nasal cavity resistance. The exposure of an antigen was carried out by generating aerosol of 3 % OVA solution for 3 min between the respirator and the nasal cavity cannula. The test drug was administered orally 60 min before the antigen exposure. The intranasal pressure between 0 to 30 min was measured continuously and the effect was expressed as an inhibition rate to that obtained for vehicle using the AUC for 30 min (on the vertical axis, intranasal pressure (cm H₂O), and on the horizontal axis, time (0 - 30 min)) as an indication. The result is shown in Table 17.

Table 17

| Compd. No. | Inhibitory Rate (%) |
|------------|---------------------|
| IA-a-5 | 96 |

Experiment 4 Activity on infiltration of eosinophils in the nasal cavity by an antigen challenge

To a Hartley male guinea pig was injected intraperitoneally cyclophosphamide (30 mg/kg), after 2 day 1 ml of suspension containing 1 mg of ovalbumin (OVA) and 100 mg of aluminum hydroxide was injected intraperitoneally. After 3 weeks, 1ml of mixture of OVA (10 μ g) and aluminum hydroxide (100 mg) was intraperitoneally injected as additional immunization to sensitize systemically. After the lapse of 3 weeks, local sensitization, each 10 μ l of 1 % OVA solution was dripped in both nasal cavities four times at 2 - 4 day intervals. After 5 - 7 days from the final sensitization,

nasal antigen challenge was performed by dripping 10 μ l of 1 % OVA solution to the guinea pigs in the both nasal cavity. Five hours after nasal challenge, the guinea pigs were exsanguinated under the anesthetization. The nasal airways were washed by infusing 10 ml of saline, and the washings were collected. The washings were centrifuged, the cell pellets were resuspended in 100 μ l of saline, and the total cells were counted by the Türk stain. Then smear samples were prepared, and the cells were classified after the May-Grünwald-Giemsa stain. The eosinophil number was determined by multiplying the rate of eosinophils with the total cells. A test compound (IA-a-5) was suspended in 0.5 % methyl cellulose, and administered orally at a dose of 1 mg/kg, 3 mg/kg, and 10 mg/kg, respectively, 1 hr before the antigen challenge. The result is shown figure 1.

We confirmed that from the above experiments 1 and 2, the compound of the present invention has a potent PGD₂-antagonistic activity; from the experiment 4, the compound of the present invention is confirmed to significantly suppress the infiltration of eosinophils; and from the experiment 3, the compound of the present invention is confirmed to be useful as a drug for treating nasal blockage.


INDUSTRIAL APPLICABILITY

The present invention provides that PGD₂ antagonists, and inhibitors for infiltration of eosinophils, being useful as a drug for treating diseases such as systemic mastocytosis and disorder of systemic mast cell activation as well as

tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion injury, inflammation and atopic dermatitis.

CLAIMS


1. A compound of the formula (I):




wherein



represents




R represents hydrogen, alkyl, alkoxy, halogen, hydroxy, acyloxy or optionally substituted arylsulfonyloxy, X represents hydrogen or alkyl, and the double bond on the α -chain has E configuration or Z configuration, provided that the compound of the formula:




wherein R^{1a} represents hydrogen, alkyl or alkoxy, X is as defined above, and the double bond on the α -chain has E configuration or Z configuration is excluded, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

2. The compound of the formula (IA):




wherein R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration, provided that the compound of the formula:




wherein R^{1a} represents hydrogen, alkyl or alkoxy, X is as defined above, and the double bond on the α -chain has E configuration or Z configuration is excluded, as claimed in Claim 1, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

3. The compound of the formula (IB):



wherein R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration as claimed in Claim 1, a pharmaceutically acceptable salt thereof, or a hydrate thereof.


4. A compound of the formula (IA-a):



wherein R¹ represents halogen, hydroxy, acyloxy or optionally substituted


arylsulfonyloxy, X is as defined above, and the double bond on the α -chain has E configuration or Z configuration, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

5. A compound of the formula (IA-b):




wherein R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

6. A compound of the formula (IA-c):




wherein R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

7. A compound of the formula (IA-d):




wherein R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

8. A compound of the formula (IA-b'):




wherein R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

9. A compound of the formula (IB-a'):



wherein R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration, a pharmaceutically acceptable salt thereof, or a hydrate thereof.

10. A compound of the formula (IB-b'):



wherein R and X are as defined above, and the double bond on the α -chain has E configuration or Z configuration, a pharmaceutically acceptable salt thereof, or a hydrate thereof.


11. The compound, the pharmaceutically acceptable salt thereof, or the hydrate thereof as claimed in anyone of Claims 1-10, wherein the double bond on the α -chain has E configuration.

12. The compound, the pharmaceutically acceptable salt thereof, or the hydrate thereof as claimed in anyone of Claims 1-10, wherein the double bond on the α -chain has Z configuration.

13. The compound, the pharmaceutically acceptable salt thereof, or the hydrate thereof as claimed in anyone of Claims 1-12, wherein R is bromo, fluoro, hydroxy, acetoxy or phenylsulfonyloxy, and X is hydrogen.


14. The compound, the pharmaceutically acceptable salt thereof, or the hydrate thereof as claimed in anyone of Claims 1-3, or 5-10 wherein R is hydrogen, methyl or methoxy and X is hydrogen.

15. A compound of the formula (V):




wherein the Y ring and R are as defined above.

16. A compound of the formula (VI):




wherein the Y ring and R are as defined above.

17. A compound of the formula (IIIa):




wherein R^2 represents acyloxy or optionally substituted arylsulfonyloxy, and R^3 represents hydroxy or halogen.

18. A compound of the formula (IIIb):



wherein R² and R³ are as defined above.

19. A compound of the formula (IIIc):



wherein R² and R³ are as defined above.

20. The compound as claimed in anyone of Claims 17-19, wherein R³ is hydroxy.

21. The compound as claimed in anyone of Claims 17-20, wherein R² is phenylsulfonyloxy or acetyloxy.

22. A pharmaceutical composition comprising the compound, the pharmaceutically acceptable salt thereof, or the hydrate thereof as claimed in anyone of Claims 1-14.

23. A PGD₂ antagonist comprising the compound, the pharmaceutically acceptable salt thereof, or the hydrate thereof as claimed in anyone of Claims 1-14,


24. A PGD₂ antagonist inhibiting infiltration of inflammatory cells comprising the compound, the pharmaceutically acceptable salt thereof, or the hydrate thereof as claimed in anyone of Claims 1-14.

25. The PGD₂ antagonist as claimed in Claim 24, wherein the inflammatory cells are eosinophils.

26. A drug for treating nasal blockage comprising the compound, the

pharmaceutically acceptable salt thereof, or the hydrate thereof as claimed in anyone of Claims 1-14.

Figure 1



INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 97/04527

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D333/38 A61K31/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| A | EP 0 608 847 A (ONO PHARMACEUTICAL CO) 3 August 1994 see abstract; claims --- | 1-26 |
| A | EP 0 171 146 A (ONO PHARMACEUTICAL CO) 12 February 1986 cited in the application see abstract; claims --- | 1-26 |
| | --- -/-- | |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 March 1998

Date of mailing of the international search report

07/04/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Paisdor, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 97/04527

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| A | M. MARTIN-SMITH ET AL.: "Benzo[b]thiophen Derivatives. Part VI. The Syntheses of 3-(2-Aminoethyl)-5-hydroxybenzo[b]thiophen and Related Compounds" JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY., 1967, LETCHWORTH GB, pages 1899-1905, XP002058536 cited in the application see page 1900, column 1: example IV --- | 15-21 |
| A | K. SENO ET AL.: "Thromboxane A2 Receptor Antagonists. III. Synthesis and Pharmacological Activity of 6,6-Dimethylbicyclo[3.1.1]heptane Derivative with a Substituted Sulfonylamino Group at C-2" CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 37, no. 6, 1989, TOKYO JP, pages 1524-1533, XP002058537 cited in the application see page 1525, chart 2: page 1526, charts 3 and 4 see abstract --- | 15-21 |
| P,A | WO 97 00853 A (SHIONOGI & CO ;OHTANI MITSUAKI (JP); ARIMURA AKINORI (JP); TSURI T) 9 January 1997 see abstract; claims --- | 1-26 |
| P,X | T. TSURI ET AL.: "Bicyclo[2.2.1]heptane and 6,6-Dimethylbicyclo[3.1.1]heptane Derivatives: Orally Active, Potent, and Selective Prostaglandin D2 Receptor Antagonists" JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 22, 1997, WASHINGTON US, pages 3504-3507, XP002058538 see page 3503; examples 18-22 ----- | 1-26 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 97/04527

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| EP 0608847 A | 03-08-94 | AT 145897 T | 15-12-96 |
| | | CA 2113787 A | 30-07-94 |
| | | DE 69401011 D | 16-01-97 |
| | | DE 69401011 T | 07-05-97 |
| | | ES 2097557 T | 01-04-97 |
| | | JP 6279395 A | 04-10-94 |
| | | US 5663417 A | 02-09-97 |
| EP 0171146 A | 12-02-86 | JP 1042938 B | 18-09-89 |
| | | JP 1557813 C | 16-05-90 |
| | | JP 61000049 A | 06-01-86 |
| | | AU 575653 B | 04-08-88 |
| | | AU 4349585 A | 19-12-85 |
| | | CA 1261826 A | 26-09-89 |
| | | DE 3565255 A | 03-11-88 |
| | | DK 260085 A | 13-12-85 |
| | | FI 852319 A | 13-12-85 |
| | | PT 80626 B | 30-11-94 |
| | | US 4792550 A | 20-12-88 |
| WO 9700853 A | 09-01-97 | AU 6137096 A | 22-01-97 |